Skip to main content
Top
Published in: Journal of Gastroenterology 6/2012

01-06-2012 | Original Article—Alimentary Tract

Partial normalization of pubertal timing in female mice with DSS colitis treated with anti-TNF-α antibody

Authors: Mark Daniel DeBoer, Jeremy Steinman, Yongli Li

Published in: Journal of Gastroenterology | Issue 6/2012

Login to get access

Abstract

Background

Inflammatory bowel disease (IBD) and resultant colitis occurring prior to puberty are frequently associated with delayed puberty and losses of growth and bone mineralization. Some of this delay may be due to colonic inflammation and associated systemic inflammation. To date no treatments for IBD have been shown to normalize the timing of puberty. Our objective in this study was to determine whether there is a normalization of the timing of puberty during treatment of colitis using monoclonal antibodies (abs) to tumor necrosis factor (TNF)-α.

Methods

We induced colitis in 23-day-old C57Bl6 female mice using 3% dextran sodium sulfate (DSS) for 7 days, followed by removal of DSS for an additional 3 days, resulting in 10 days of worsening colitis. DSS-treated mice received either TNF-α ab or Control ab on days 4 and 8 of colitis, while non-colitic Control mice received injections of TNF-α ab (Control + TNF-α ab). All groups were followed for the timing of vaginal opening until day of life 33, when they were euthanized for serum and colon collection.

Results

The DSS + TNF-α ab group had lower levels of systemic interleukin (IL)-6 and a partial normalization of the timing of vaginal opening compared to the DSS + Control ab group. There were no differences in weight gain, growth, or colon histological inflammatory scores between the DSS + TNFα ab and DSS + Control ab groups over the course of the experiment.

Conclusions

We conclude that anti-TNF-α ab treatment causes a partial normalization of pubertal timing coincident with decreased systemic inflammation in DSS colitis. These data may have implications regarding growth and bone mineralization outcomes in pediatric IBD.
Literature
1.
go back to reference Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res. 2003;53:205–10.PubMed Ballinger AB, Savage MO, Sanderson IR. Delayed puberty associated with inflammatory bowel disease. Pediatr Res. 2003;53:205–10.PubMed
2.
go back to reference Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009;48:168–74.PubMedCrossRef Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009;48:168–74.PubMedCrossRef
3.
go back to reference Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics. 2006;118:124–9.PubMedCrossRef Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics. 2006;118:124–9.PubMedCrossRef
4.
go back to reference Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr. 2006;43:144–55.PubMedCrossRef Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr. 2006;43:144–55.PubMedCrossRef
5.
go back to reference DeBoer MD, Barnes BH. The importance of treatment regimens and pubertal status for growth in IBD. J Pediatr. 2009;154:936–7.PubMed DeBoer MD, Barnes BH. The importance of treatment regimens and pubertal status for growth in IBD. J Pediatr. 2009;154:936–7.PubMed
6.
go back to reference Dubner SE, Shults J, Baldassano RN, Zemel BS, Thayu M, Burnham JM, Herskovitz RM, Howard KM, Leonard MB. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn’s disease. Gastroenterology. 2009;136:123–30.PubMedCrossRef Dubner SE, Shults J, Baldassano RN, Zemel BS, Thayu M, Burnham JM, Herskovitz RM, Howard KM, Leonard MB. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn’s disease. Gastroenterology. 2009;136:123–30.PubMedCrossRef
7.
go back to reference Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:416–23.PubMedCrossRef Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:416–23.PubMedCrossRef
8.
go back to reference Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6:1378–84.PubMedCrossRef Thayu M, Leonard MB, Hyams JS, Crandall WV, Kugathasan S, Otley AR, Olson A, Johanns J, Marano CW, Heuschkel RB, Veereman-Wauters G, Griffiths AM, Baldassano RN. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn’s disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6:1378–84.PubMedCrossRef
9.
go back to reference Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1483–91.PubMed Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol. 2001;281:R1483–91.PubMed
10.
go back to reference Farooqi IS. Leptin and the onset of puberty: insights from rodent and human genetics. Semin Reprod Med. 2002;20:139–44.PubMedCrossRef Farooqi IS. Leptin and the onset of puberty: insights from rodent and human genetics. Semin Reprod Med. 2002;20:139–44.PubMedCrossRef
11.
12.
go back to reference Kalra PS, Sahu A, Kalra SP. Interleukin-1 inhibits the ovarian steroid-induced luteinizing hormone surge and release of hypothalamic luteinizing hormone-releasing hormone in rats. Endocrinology. 1990;126:2145–52.PubMedCrossRef Kalra PS, Sahu A, Kalra SP. Interleukin-1 inhibits the ovarian steroid-induced luteinizing hormone surge and release of hypothalamic luteinizing hormone-releasing hormone in rats. Endocrinology. 1990;126:2145–52.PubMedCrossRef
13.
go back to reference Rivier C, Vale W. Cytokines act within the brain to inhibit luteinizing hormone secretion and ovulation in the rat. Endocrinology. 1990;127:849–56.PubMedCrossRef Rivier C, Vale W. Cytokines act within the brain to inhibit luteinizing hormone secretion and ovulation in the rat. Endocrinology. 1990;127:849–56.PubMedCrossRef
14.
go back to reference Nappi RE, Rivest S. Effect of immune and metabolic challenges on the luteinizing hormone-releasing hormone neuronal system in cycling female rats: an evaluation at the transcriptional level. Endocrinology. 1997;138:1374–84.PubMedCrossRef Nappi RE, Rivest S. Effect of immune and metabolic challenges on the luteinizing hormone-releasing hormone neuronal system in cycling female rats: an evaluation at the transcriptional level. Endocrinology. 1997;138:1374–84.PubMedCrossRef
15.
go back to reference DeBoer MD, Li Y. Puberty is delayed in male mice with dextran sodium sulfate colitis out of proportion to changes in food intake, body weight, and serum levels of leptin. Pediatr Res. 2011;69:34–9.PubMedCrossRef DeBoer MD, Li Y. Puberty is delayed in male mice with dextran sodium sulfate colitis out of proportion to changes in food intake, body weight, and serum levels of leptin. Pediatr Res. 2011;69:34–9.PubMedCrossRef
16.
go back to reference DeBoer MD, Li Y, Cohn S. Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone. J Gastroenterol. 2010;45:277–84.PubMedCrossRef DeBoer MD, Li Y, Cohn S. Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone. J Gastroenterol. 2010;45:277–84.PubMedCrossRef
17.
go back to reference Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132:863–73. (quiz 1165–1166).PubMedCrossRef Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132:863–73. (quiz 1165–1166).PubMedCrossRef
18.
go back to reference Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS. Infliximab improves inflammation and anthropometric measures in pediatric Crohn’s disease. J Gastroenterol Hepatol. 2010;25:810–6.PubMedCrossRef Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS. Infliximab improves inflammation and anthropometric measures in pediatric Crohn’s disease. J Gastroenterol Hepatol. 2010;25:810–6.PubMedCrossRef
19.
go back to reference Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis. 2007;13:424–30.PubMedCrossRef Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis. 2007;13:424–30.PubMedCrossRef
20.
go back to reference Nelson JF, Karelus K, Felicio LS, Johnson TE. Genetic influences on the timing of puberty in mice. Biol Reprod. 1990;42:649–55.PubMedCrossRef Nelson JF, Karelus K, Felicio LS, Johnson TE. Genetic influences on the timing of puberty in mice. Biol Reprod. 1990;42:649–55.PubMedCrossRef
21.
go back to reference Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn’s disease in mice. Gastroenterology. 2001;121:1428–36.PubMedCrossRef Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn’s disease in mice. Gastroenterology. 2001;121:1428–36.PubMedCrossRef
22.
go back to reference Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, Pizarro TT, Cominelli F. TNF-alpha neutralization ameliorates the severity of murine Crohn’s-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA. 2003;100:8366–71.PubMedCrossRef Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, Pizarro TT, Cominelli F. TNF-alpha neutralization ameliorates the severity of murine Crohn’s-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA. 2003;100:8366–71.PubMedCrossRef
24.
go back to reference Eckert KL, Wilson DM, Bachrach LK, Anhalt H, Habiby RL, Olney RC, Hintz RL, Neely EK. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics. 1996;97:517–9.PubMed Eckert KL, Wilson DM, Bachrach LK, Anhalt H, Habiby RL, Olney RC, Hintz RL, Neely EK. A single-sample, subcutaneous gonadotropin-releasing hormone test for central precocious puberty. Pediatrics. 1996;97:517–9.PubMed
25.
go back to reference DeBoer MD, Marks DL. Therapy insight: use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab. 2006;2:459–66.PubMedCrossRef DeBoer MD, Marks DL. Therapy insight: use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab. 2006;2:459–66.PubMedCrossRef
26.
go back to reference Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Scholmerich J, Gross V, Falk W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol. 1997;107:353–8.PubMedCrossRef Kojouharoff G, Hans W, Obermeier F, Mannel DN, Andus T, Scholmerich J, Gross V, Falk W. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice. Clin Exp Immunol. 1997;107:353–8.PubMedCrossRef
27.
go back to reference Bento AF, Leite DF, Claudino RF, Hara DB, Leal PC, Calixto JB. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol. 2008;84:1213–21.PubMedCrossRef Bento AF, Leite DF, Claudino RF, Hara DB, Leal PC, Calixto JB. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol. 2008;84:1213–21.PubMedCrossRef
28.
go back to reference Wong ML, Bongiorno PB, Rettori V, McCann SM, Licinio J. Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci USA. 1997;94:227–32.PubMedCrossRef Wong ML, Bongiorno PB, Rettori V, McCann SM, Licinio J. Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci USA. 1997;94:227–32.PubMedCrossRef
29.
go back to reference Marshall JC, Kelch RP. Gonadotropin-releasing hormone: role of pulsatile secretion in the regulation of reproduction. N Engl J Med. 1986;315:1459–68.PubMedCrossRef Marshall JC, Kelch RP. Gonadotropin-releasing hormone: role of pulsatile secretion in the regulation of reproduction. N Engl J Med. 1986;315:1459–68.PubMedCrossRef
30.
go back to reference Malik S, Wong SC, Bishop J, Hassan K, McGrogan P, Ahmed SF, Russell RK. Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr. 2011;52:31–7.PubMedCrossRef Malik S, Wong SC, Bishop J, Hassan K, McGrogan P, Ahmed SF, Russell RK. Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr. 2011;52:31–7.PubMedCrossRef
31.
go back to reference Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn’s disease. Am J Gastroenterol. 2005;100:2031–5.PubMedCrossRef Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn’s disease. Am J Gastroenterol. 2005;100:2031–5.PubMedCrossRef
32.
go back to reference DeBoer MD, Barnes BH, Stygles NA, Sutphen JL, Borowitz SM. Changes in inflammation and quality of life after a single dose of infliximab during on-going treatment: Differences between patients with and without IBD symptoms at time of administration. J Pediatr Gastroenterol Nutr. 2011. doi:10.1097/MPG.0b013e3182382ee3 DeBoer MD, Barnes BH, Stygles NA, Sutphen JL, Borowitz SM. Changes in inflammation and quality of life after a single dose of infliximab during on-going treatment: Differences between patients with and without IBD symptoms at time of administration. J Pediatr Gastroenterol Nutr. 2011. doi:10.​1097/​MPG.​0b013e3182382ee3​
33.
go back to reference Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMedCrossRef Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–76.PubMedCrossRef
Metadata
Title
Partial normalization of pubertal timing in female mice with DSS colitis treated with anti-TNF-α antibody
Authors
Mark Daniel DeBoer
Jeremy Steinman
Yongli Li
Publication date
01-06-2012
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 6/2012
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0542-y

Other articles of this Issue 6/2012

Journal of Gastroenterology 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine